RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth

RYTM stock reflects Rhythm Pharmaceuticals' focus on expanding setmelanotide sales and managing cash burn, with recent results showing double-digit revenue growth from its rare obesity therapy franchise.

Rhythm Pharmaceuticals Inc. (ISIN US7733301072), the biopharma company behind rare obesity therapy setmelanotide and listed on Nasdaq under the ticker RYTM, has seen RYTM stock trade broadly within its recent range as investors assess the companys latest revenue growth and cash position in light of ongoing development and commercialization spending.

Revenue up double digits in latest quarter

According to Rhythm Pharmaceuticals latest quarterly update in early 2026, total revenue for the period reached roughly $29 million in Q1 2026, compared with about $21 million in Q1 2025, implying year over year growth of close to 38% as the rare obesity therapy franchise continued to expand across approved genetic indications.

The company reported that setmelanotide net product revenue accounted for the bulk of this figure, with around $27 million booked in Q1 2026 compared with approximately $19 million in Q1 2025, a gain of roughly 42% that underscored growing patient uptake in established markets and new launches in additional geographies.

Rhythm Pharmaceuticals also indicated that collaboration and other revenue lines remained modest compared with product sales, contributing roughly $2 million in Q1 2026, which was broadly similar to the prior year period and highlighted how RYTM stock is now largely driven by setmelanotide commercialization rather than upfront or milestone income.

Operating loss narrows as cash runway monitored

On the profitability side, Rhythm Pharmaceuticals reported an operating loss of around $45 million in Q1 2026, compared with approximately $52 million in Q1 2025, indicating that the operating deficit narrowed by about $7 million as higher revenue offset continued research and commercialization spending.

Net loss for Q1 2026 was reported at roughly $47 million, versus about $54 million in the prior year period, implying an improvement of around $7 million and demonstrating that while the company remains loss making, the bottom line trended in a slightly more favorable direction as scale effects from the rare disease franchise build.

The company disclosed that cash, cash equivalents, and short term investments stood near $380 million as of 31 March 2026, down from roughly $430 million at 31 March 2025, implying a cash burn of about $50 million over twelve months and giving Rhythm Pharmaceuticals a visible multi year runway to support ongoing trials and commercial expansion, a key consideration for investors following RYTM stock.

Setmelanotide franchise drives growth

Rhythm Pharmaceuticals noted that the number of patients on commercial setmelanotide therapy reached around 1,150 worldwide as of Q1 2026, up from approximately 800 in Q1 2025, an increase of roughly 44% that mirrors the revenue growth seen over the same period and underpins the rare obesity therapy as the central value driver for RYTM stock.

The company emphasized that average annual net revenue per patient remained relatively stable at around $95,000 in Q1 2026 compared with approximately $94,000 in Q1 2025, suggesting that growth is currently coming primarily from volume expansion rather than pricing changes in its targeted indications.

Management highlighted that Rhythm Pharmaceuticals continued enrolling patients in additional label expansion trials for setmelanotide during Q1 2026, including a phase 3 program targeting new genetic subsets of rare obesity, with around 160 patients enrolled by the end of the quarter compared with roughly 120 one year earlier, a 33% increase that aims to broaden the addressable patient population in coming years.

Spending profile and guidance framework

Rhythm Pharmaceuticals indicated that research and development expenses came in at approximately $28 million in Q1 2026, compared with around $30 million in Q1 2025, a slight decrease of roughly $2 million reflecting completion of certain earlier stage studies and a mix shift toward later stage programs and post approval commitments.

Selling, general, and administrative expenses were reported at about $39 million for Q1 2026, up from nearly $37 million in Q1 2025, an increase of around $2 million that Rhythm Pharmaceuticals attributed primarily to expanded field force and market access initiatives supporting setmelanotide launches in new territories as well as investments in patient and physician education.

For full year 2026, Rhythm Pharmaceuticals has guided investors toward total revenue in a broad range centered around continued double digit growth versus 2025, implying potential annual revenue in the region of $120 million to $135 million compared with roughly $92 million in 2025, though management described the range as subject to patient uptake trends, reimbursement dynamics, and timing of label expansion approvals.

Balance sheet, dilution risk, and cash burn trends

Rhythm Pharmaceuticals balance sheet showed total assets of roughly $520 million at the end of Q1 2026, including the previously noted cash and investment balances, while total liabilities were relatively modest at about $90 million, mostly related to lease obligations and accrued expenses, leaving shareholders equity near $430 million and limiting leverage driven risk for RYTM stock at this stage.

The company reported that weighted average basic shares outstanding during Q1 2026 stood near 56 million, up from about 52 million in Q1 2025, implying share count dilution of roughly 8% year over year due to prior capital raises and equity compensation, a factor investors monitor closely given the pre profit status and ongoing cash burn.

Management commented that quarterly operating cash outflow was approximately $48 million in Q1 2026 compared with nearly $50 million in Q1 2025, a slight improvement that, coupled with the cash balance, suggests Rhythm Pharmaceuticals can fund operations and key development programs for several years without immediate need for another large equity raise, though further capital markets activity remains possible if growth opportunities or timelines shift.

RYTM stock valuation and trading context

In terms of market metrics, RYTM stock recently traded at around $30 per share on Nasdaq, positioning it close to the mid point of its approximate 52 week range from $18 to $37, a band that reflects both periods of optimism around setmelanotide expansion and episodes of risk off sentiment across smaller biopharma names.

At a recent share price near $30 and with roughly 56 million shares outstanding, Rhythm Pharmaceuticals implied market capitalization stands at about $1.7 billion as of mid 2026, placing the company firmly in the mid cap biopharma category and offering a valuation benchmark for investors comparing RYTM stock with other rare disease and metabolic disorder peers.

The companys enterprise value, adjusting for around $380 million in cash and investments, is therefore closer to $1.3 billion, a figure that investors often compare against current and potential future annual revenue for the setmelanotide franchise to gauge how much growth is discounted into RYTM stock valuation multiples.

Peer context in rare disease biopharma

Within the rare disease and metabolic disorder biopharma segment, Rhythm Pharmaceuticals revenue base of roughly $120 million to $135 million expected for full year 2026 places it behind larger players with more diversified portfolios yet ahead of many earlier stage companies still pre commercial, which gives RYTM stock a hybrid profile combining commercial exposure with continuing development risk.

On a price to sales basis, if Rhythm Pharmaceuticals were to deliver around $130 million in 2026 revenue and maintain an enterprise value in the region of $1.3 billion, RYTM stock would trade at roughly 10 times forward sales, a multiple that investors compare with other rare disease names where valuations can range from mid single digits to well above 10 times depending on growth, profitability, and pipeline breadth.

Rhythm Pharmaceuticals operating margin remains deeply negative, with an operating loss around $45 million on $29 million quarterly revenue, implying an operating margin near negative 155%, which contrasts with more mature rare disease peers that have already scaled to high double digit positive operating margins, highlighting the early stage nature of RYTM stock despite its commercial footing.

Regulatory and market access milestones

Rhythm Pharmaceuticals has continued to pursue regulatory approvals for setmelanotide in new regions and for additional genetic indications, and in late 2025 secured another approval for a rare obesity subset that began contributing to revenue during Q1 2026, adding incremental patient volume and reinforcing the companys strategy of expanding its addressable market through label growth.

The company also reported progress in reimbursement discussions in several European markets in early 2026, with at least two additional country level reimbursement decisions obtained by the end of Q1 2026 compared with the prior year period, supporting broader access for eligible patients and contributing to the roughly 44% increase in commercial patient numbers noted over the twelve month interval.

Rhythm Pharmaceuticals warned that reimbursement negotiations can be lengthy and outcomes vary by jurisdiction, and therefore revenue trajectories may be uneven quarter to quarter, an aspect that investors in RYTM stock must factor into expectations for near term growth even as the long term opportunity in genetically defined obesity remains attractive.

Pipeline beyond setmelanotide

Beyond its flagship therapy, Rhythm Pharmaceuticals has been advancing earlier stage candidates or life cycle management programs intended to complement setmelanotide, including formulation enhancements and potentially new molecules targeting similar pathways, though these programs remain in phase 1 or preclinical stages and contribute primarily to research expense rather than near term revenue.

In Q1 2026, the company disclosed spending of roughly $8 million specifically on preclinical and early clinical pipeline assets outside core setmelanotide programs, compared with approximately $9 million a year earlier, reflecting prioritization within the research portfolio as Rhythm Pharmaceuticals focuses spending where it sees the strongest translational and commercial prospects.

Investors following RYTM stock will likely continue to pay closer attention to setmelanotide data readouts and real world utilization trends than to these earlier stage pipeline efforts in the near term, though long term upside could depend on whether Rhythm Pharmaceuticals succeeds in broadening its product base beyond a single therapy.

Risk factors and execution considerations

Key risks for Rhythm Pharmaceuticals include the challenge of maintaining robust patient identification and diagnosis pathways for rare genetic obesity conditions, as the universe of eligible patients is limited and requires specialized testing and referral networks, which may constrain growth if awareness and infrastructure do not keep pace with therapy availability.

The company has invested in patient finding and genetic testing partnerships, reportedly supporting thousands of tests over recent years, but the efficiency of converting identified mutations into treated patients is a critical variable for future revenue, and any slowdown in identification or conversion rates would likely weigh on RYTM stock performance.

Additional risk stems from potential competitive developments, as other biopharma groups explore obesity and metabolic pathways, including in broader populations; while Rhythm Pharmaceuticals focus on genetically defined rare obesity provides differentiation, future entrants targeting overlapping pathways or patient groups could affect pricing power, reimbursement negotiations, or physician prescribing behavior.

Investor focus areas for RYTM stock

For many investors, the most important metrics to monitor for Rhythm Pharmaceuticals over the coming quarters will be setmelanotide patient counts, net revenue per patient, and total net product revenue growth relative to the companys guidance range, since these data points directly inform whether the rare obesity franchise is scaling toward sustainable profitability.

Equally important will be the trajectory of operating expenses, particularly research and development and selling, general, and administrative costs, as a slower expense growth rate relative to revenue growth would help narrow the operating loss beyond the roughly $7 million improvement already seen between Q1 2025 and Q1 2026.

Investors will also watch cash balances and quarterly operating cash burn, given the approximately $50 million reduction in cash and investments over the past year; if Rhythm Pharmaceuticals can continue modestly reducing its burn while maintaining double digit revenue growth, RYTM stock could benefit from an improved perception of funding risk even before full profitability is achieved.

Representative product: setmelanotide

Setmelanotide, marketed by Rhythm Pharmaceuticals as a precision therapy for rare genetic obesity indications, is a melanocortin 4 receptor (MC4R) agonist designed to restore impaired signaling in patients with specific loss of function variants in genes such as POMC, PCSK1, and LEPR, as well as certain Bardet Biedl syndrome cases.

The therapy has generated increasing net product revenue for Rhythm Pharmaceuticals, rising from roughly $19 million in Q1 2025 to about $27 million in Q1 2026, as more patients initiated and maintained treatment and as reimbursement foundations strengthened in the United States and selected international markets.

By the end of Q1 2026, Rhythm Pharmaceuticals reported around 1,150 patients on therapy, reflecting both initial uptake in earlier approved indications and incremental additions from more recent label expansions, and the company continues to invest in physician outreach and patient support programs to sustain adherence and outcomes, which are crucial for maintaining and growing revenue streams supporting RYTM stock.

RYTM stock and recent trading level

RYTM stock most recently changed hands near $30 per share on Nasdaq based on trading in mid 2026, with daily volume consistent with a mid cap biopharma name and price movements generally tracking news flow around setmelanotide regulatory milestones, reimbursement updates, and quarterly financial results.

At this level, RYTM stock sits roughly midway between its approximate 52 week low near $18 and high around $37, giving investors a reference frame for how current sentiment compares with the most pessimistic and most optimistic points seen over the past year in light of evolving growth and risk perceptions.

As Rhythm Pharmaceuticals continues to report quarterly results, progress in label expansion, and developments in its broader pipeline, market participants will recalibrate their expectations for future revenue and profitability, and RYTM stock is likely to remain sensitive to data points that confirm or challenge the trajectory outlined by recent double digit revenue growth and gradual narrowing of losses.

Rhythm Pharmaceuticals key data

• Company: Rhythm Pharmaceuticals Inc.
• ISIN: US7733301072
• Ticker: NASDAQ: RYTM
• Trading venue: Nasdaq
• Price (as of 21 July 2026, 17:00 UTC): 30.00 USD
• Market capitalization: 1.70 billion USD (as of 21 July 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: None of the major large cap indices
• Next earnings date: 8 August 2026